✦ LIBER ✦

Staging of chronic myeloid leukemia in the imatinib era : An Evaluation of the World Health Organization Proposal

✍ Scribed by Jorge E. Cortes; Moshe Talpaz; Susan O'Brien; Stefan Faderl; Guillermo Garcia-Manero; Alessandra Ferrajoli; Srdan Verstovsek; Mary B. Rios; Jenny Shan; Hagop M. Kantarjian

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 367 KB
Volume: 106
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21756

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of chronic myeloid leukemia in

Treatment of chronic myeloid leukemia in the imatinib era : Perspective from a developing country

✍ Zeba Aziz; Javaid Iqbal; Mohammad Akram; Sarah Saeed 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB

Expanding Nilotinib Access in Clinical T

Expanding Nilotinib Access in Clinical Trials (ENACT) : An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase

✍ Franck E. Nicolini; Anna Turkina; Zhi-Xiang Shen; Neil Gallagher; Saengsuree Joo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 2 views

## Abstract ## BACKGROUND: Nilotinib is a selective, potent BCR‐ABL inhibitor. Previous studies demonstrated the efficacy and safety of nilotinib in Philadelphia chromosome‐positive chronic myeloid leukemia patients in chronic phase (CML‐CP) or accelerated phase who failed prior imatinib. ## METH